Standard targeted therapy implementation for driver alterations newly identified by comprehensive genomic profiling in clinically driver-negative advanced NSCLC.
- DOI
- 10.1016/j.lungcan.2026.109625
- Published
- 2026 Sep 15
- Container
- Lung cancer (Amsterdam, Netherlands)
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.lungcan.2026.109625,
title = {Standard targeted therapy implementation for driver alterations newly identified by comprehensive genomic profiling in clinically driver-negative advanced NSCLC.},
author = {Ando T and Fujii K and Ikushima H and Watanabe K and Oda K and Kage H},
year = {2026},
journal = {Lung cancer (Amsterdam, Netherlands)},
doi = {10.1016/j.lungcan.2026.109625},
url = {https://doi.org/10.1016/j.lungcan.2026.109625}
}RIS
TY - JOUR TI - Standard targeted therapy implementation for driver alterations newly identified by comprehensive genomic profiling in clinically driver-negative advanced NSCLC. AU - Ando T AU - Fujii K AU - Ikushima H AU - Watanabe K AU - Oda K AU - Kage H PY - 2026 JO - Lung cancer (Amsterdam, Netherlands) DO - 10.1016/j.lungcan.2026.109625 UR - https://doi.org/10.1016/j.lungcan.2026.109625 ER -
APA
T, A., K, F., H, I., K, W., K, O., & H, K. (2026). Standard targeted therapy implementation for driver alterations newly identified by comprehensive genomic profiling in clinically driver-negative advanced NSCLC.. Lung cancer (Amsterdam, Netherlands). https://doi.org/10.1016/j.lungcan.2026.109625
Source records
- pubmed · retrieved 2026-09-25T08:52:39.999Z
- europe-pmc · retrieved 2026-09-25T08:52:40.011Z